The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

LVIII.br

Path: Pleuroparenchymal fibrosis/fibroelastosis (PPFE)

Publications

Parish JM, Muhm JR, Leslie KO

Upper lobe pulmonary fibrosis associated with high-dose chemotherapy containing BCNU for bone marrow transplantation.

Mayo Clinic proceedings 2003 May;78;630-4 — 2003 May — 630-4

Hasleton PS, O'Driscoll BR, Lynch P, Webster A, Kalra SJ, Gattamaneini HR, Woodcock AA, Poulter LW

Late BCNU lung: a light and ultrastructural study on the delayed effect of BCNU on the lung parenchyma.

The Journal of pathology 1991 May;164;31-6 — 1991 May — 31-6

Bailey CC, Marsden HB, Jones PH

Fatal pulmonary fibrosis following 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) therapy.

Cancer 1978 Jul;42;74-6 — 1978 Jul — 74-6